Drug MNCs for keeping patient aid plan out of trade margin formula

The Organisation of Pharmaceutical Producers of India (OPPI) recommended excluding Patient Assistance Programmes (PAPs) from Trade Margin Rationalisation to maintain affordability for patients. They noted that PAPs are crucial for providing access to expensive drugs, especially for oncology and rare diseases. OPPI also sought exemption for patented and orphan drugs from government-set price controls and opposed post-patent price cuts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7szSUgu
via IFTTT